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Abstract
Bacterial lipoproteins (BLP) induce innate immune responses in mammals by activating heterodimeric receptor complexes
containing Toll-like receptor 2 (TLR2). TLR2 signaling results in nuclear factor-kappaB (NF-kB)-dependent upregulation of
anti-apoptotic factors, anti-oxidants and cytokines, all of which have been implicated in radiation protection. Here we
demonstrate that synthetic lipopeptides (sLP) that mimic the structure of naturally occurring mycoplasmal BLP significantly
increase mouse survival following lethal total body irradiation (TBI) when administered between 48 hours before and
24 hours after irradiation. The TBI dose ranges against which sLP are effective indicate that sLP primarily impact the
hematopoietic (HP) component of acute radiation syndrome. Indeed, sLP treatment accelerated recovery of bone marrow
(BM) and spleen cellularity and ameliorated thrombocytopenia of irradiated mice. sLP did not improve survival of irradiated
TLR2-knockout mice, confirming that sLP-mediated radioprotection requires TLR2. However, sLP was radioprotective in
chimeric mice containing TLR2-null BM on a wild type background, indicating that radioprotection of the HP system by sLP
is, at least in part, indirect and initiated in non-BM cells. sLP injection resulted in strong transient induction of multiple
cytokines with known roles in hematopoiesis, including granulocyte colony-stimulating factor (G-CSF), keratinocyte
chemoattractant (KC) and interleukin-6 (IL-6). sLP-induced cytokines, particularly G-CSF, are likely mediators of the
radioprotective/mitigative activity of sLP. This study illustrates the strong potential of LP-based TLR2 agonists for anti-
radiation prophylaxis and therapy in defense and medical scenarios.
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Introduction
Acute high dose radiation exposure affecting large populations
could result from multiple potentialdisaster scenarios, thus dictating
the need for safe and effective medical radiation countermeasures
(MRC) [1,2]. Use of MRC would be aimed at reducing near-term
mortality as well as limiting radiation damage that causes long-term
adverse health effects [3,4]. In addition, large numbers of people are
routinely exposed to anti-cancer radiation therapy and MRC could
be useful in ameliorating the negative side effects of the therapy and
enabling safe application of higher doses of radiation [5,6].
The biological effects of radiation on mammalian organisms are
strongly dependent upon the dose of radiation received [4]. Acute
radiation syndrome (ARS) developing from whole-body or
significant partial-body irradiation can involve hematopoietic
(HP), gastrointestinal (GI), and cerebrovascular components [7].
Cerebrovascular damage caused by massive neuronal apoptosis is
induced by the highest radiation doses (more than 10–20 Gy in
humans) and invariably leads to death within several days. In
contrast, mortality from HP syndrome (induced by TBI doses of 1
Gy or more in humans) and GI syndrome (induced by 5 Gy or
more) occurs with lower frequency and more slowly (over weeks
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33044rather than days) and is more likely to be amenable to
pharmacological countermeasures. Notably, GI syndrome always
occurs in concert with HP syndrome, and the HP component can
play a major role in mortality even if it stems primarily from GI
damage. For example, death of patients with GI ARS is frequently
caused by sepsis resulting from death of epithelial cells lining the
GI tract and loss of GI tract integrity together with concomitant
loss of immune/hematopoietic function. Even though isolated HP
syndrome is induced by lower radiation doses and has a better
prognosis than GI syndrome, it is a serious concern, typically
resulting in 50% mortality within ,3–6 weeks. Moreover, since
HP syndrome occurs at the lowest ARS-inducing dose range of
irradiation, it would likely affect the largest proportion of an
exposed population.
There are a number of potential MRC currently at different
stages of development, which fall roughly into two categories
depending upon their primary mechanism of action: immuno-
modulators/cytokines/growth factors [8,9,10] and antioxidants/
free radical scavengers [11,12]. In large part, the focus on
cytokines and growth factors has been based on their potential
ability to act as radiomitigators enhancing recovery of the HP
system from radiation damage, as demonstrated in multiple in
vitro and in vivo models [8,13]. These include stem cell factor
(SCF) [14,15], FMS-like tyrosine kinase-3 (FLT-3) ligand [16,17],
interleukin-1 fragment (IL-1b-rd) [18], keratinocyte growth factor
(KGF) [19], and G-CSF [9]. Some cytokines have received FDA
approval for treatment of neutropenia and thrombocytopenia
caused by anti-cancer radiotherapy and chemotherapy, and
several are in development [2,3,20]. The anti-radiation potential
of antioxidants and free radical scavengers derives from their
ability to reduce levels of reactive oxygen species (ROS) induced
by radiation, thus decreasing DNA damage, lipid peroxidation
and other types of chemical modification damage [12]. This
category of anti-radiation drugs is represented by the naturally
occurring antioxidant vitamin E and the synthetic phosphorothio-
ate amifostine (WR-2721), which is currently used to minimize the
side effects of radiation therapy [21]. Efficacy of this class of agents
is limited to prophylaxis of radiation injury.
Since ARS involves massive apoptosis in radiosensitive tissues
such as the HP system and GI tract [22,23,24], we have focused
on developing novel strategies to reduce radiation damage and
lethality by targeting cellular pathways that regulate apoptosis.
One such pathway involves a major regulator of all aspects of
immune responses, NF-kB, which mediates transcriptional
upregulation of anti-apoptotic genes [25]. The survival-promoting
capacity of this pathway is indicated by the fact that constitutive
activation of NF-kB is a common feature of tumors [26]. We
hypothesized that pharmacological activation of NF-kB might be a
promising strategy for both radioprotection and radiomitigation
since NF-kB regulates expression of not only anti-apoptotic genes
[25], but also those encoding (i) cytokines and growth factors that
induce proliferation and survival of HP and other stem cells
[27,28]; and (ii) potent ROS-scavenging antioxidant proteins, such
as MnSOD (SOD-2) [29]. The rationale for exploring this
approach was further strengthened by the finding that mice with
a genetic defect in NF-kB signaling displayed heightened GI
radiosensitivity [30].
To develop pharmacological activators of NF-kB, we exploited
one of the natural mechanisms by which the innate immune
system responds to microbial infections. Various pathogen-
associated molecular patterns (PAMPs) are recognized by host
cells due to their specific interaction with Toll-like receptors
(TLRs), which leads to activation of NF-kB [31]. We hypothesized
that drugs based on PAMPs might be safe since they are
commonly present in humans [32]. These features, as well as
significant in vivo radioprotective/mitigative efficacy, were
demonstrated for an NF-kB-activating TLR5 agonist based on
bacterial flagellin [33]. In the current work, we investigated use of
another type of PAMP, TLR2/6 agonistic synthetic mycoplasma-
derived lipoproteins (sLP), as radiation countermeasures.
Here we demonstrate that synthetic mimetics of diacylated
mycoplasma lipopeptides (sLP; e.g., Pam2-CSKKKK), agonists of
TLR2, have significant in vivo radioprotective and radiomitigative
efficacy. A single injection of sLP given either before or after
irradiation increased the survival of mice exposed to doses of total
body irradiation (TBI) inducing mortality primarily from the HP
component of ARS, but not those inducing GI-related ARS, and
had beneficial effects on bone marrow and spleen cellularity and
platelet levels. sLP injection led to strong induction of a number of
cytokines with known roles in hematopoiesis, which likely
contributes to the radioprotective/mitigative activity of sLP.
Finally, through comparison of SLP-mediated cytokine induction
and radiation protection in reciprocal chimeric mice with either
wild type or TLR2-null bone marrow, we demonstrated that the
ability of SLP to protect against radiation damage to the HP
system is, at least in part, due to indirect effects of responses
initiated in non-bone marrow-derived cells. Overall, this study
provides a foundation for development of LP-based TLR2 agonists
for anti-radiation prophylaxis and therapy in defense and medical
scenarios.
Results
A synthetic mycoplasma lipopeptide mimetic (sLP)
protects mice from radiation-induced death
To test our hypothesis that pharmacologic imitation of BLP-
mediated TLR2 stimulation might be an effective anti-radiation
strategy, we used a synthetic mimetic of a mycoplasma di-
palmitoylated lipopeptide (R,R-Pam2Cys-SKKKK, sLP) as a
TLR2 ligand. We chose to focus on LPs from mycoplasma rather
than other types of bacteria since these organisms typically exist
asymptomatically as part of the commensal microflora in
mammals [32] and their products could, therefore, be expected
to have low toxicity and immunogenicity. Moreover, sLP was
previously shown to mimic the NF-kB-induction activity of natural
Mycoplasma-derived lipoproteins [34,35,36,37]. We confirmed that
sLP activated an NF-kB-dependent LacZ reporter in cultured
HEK293 cells expressing TLR2/6 or TLR2/CD14 receptors, but
not in TLR2/1 expressing reporter cells or in TLR-negative
HEK293 cells (data not shown).
Groups of female ICR mice (n=15/group) were injected
subcutaneously (sc) with a wide range of doses of sLP followed by
exposure to 10 Gy total body gamma-irradiation (TBI) 24 hours
(h) after sLP injection, and were then monitored for survival for 30
days. 10 Gy is equivalent to an LD100/30 dose in ICR mice,
resulting in death of 100% of mice within 30 days (Figure 1). As
shown in Figure 1A, pretreatment with a single dose of sLP
dramatically improved the survival of mice exposed to this
otherwise lethal dose of TBI. The survival benefit was dose-
dependent. A substantial, although not statistically significant,
increase in survival was observed even with the lowest tested dose
of 4 mg/kg sLP (20% survival as compared to 0% in the PBS-
injected control group, p=0.25). Survival increased to 46% with
12 mg/kg sLP and 82% with 40 mg/kg sLP (p=0.02 and 0.0001,
respectively, for comparison to the PBS-treated group). Doses of
40–1200 mg/kg resulted in similar levels of radioprotection (82–
95% survival, p,0.05 for comparison to the PBS-treated group,
p.0.05 for all pair-wise comparisons between different sLP dose
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optimal radioprotective dose of sLP for use in subsequent
experiments. Specificity of the radioprotective effect of sLP
mimicking Mycoplasma-derived lipopeptides was indicated by our
finding that (Pam3)-CSKKKK, a synthetic lipopeptide mimicking
bacterial-derived that lacks the lipid moiety typical of Mycoplasma-
derived lipopeptides and does not activate NF-kB-dependent
reporter expression in vitro, did not improve survival of irradiated
mice (data not shown).
In order to determine the time window for effective adminis-
tration of sLP relative to radiation exposure, we injected female
ICR mice sc with 40 mg/kg sLP at different time points prior to 10
Gy TBI. The 30-day survival rate was 0% for both the control
group injected with PBS at 24 h prior to TBI and the group
injected with sLP at 72 h prior to TBI (Figure 1B). However,
injection of sLP at any of the other tested times (48, 36, 24, 12, 6,
3, 1 and 0.5 h prior to TBI) resulted in a significant increase in 30-
day survival relative to PBS injection (40–100% survival, p=0.02
for comparison of sLP-treated groups with the lowest 30-day
survival (40%) as compared to the PBS-treated group). Injection of
sLP 24 h prior to TBI resulted in 100% survival and was therefore
selected as the optimal radioprotective time of administration. It is
notable, however, that the effective time window for achieving
significant radioprotection with sLP is broad, ranging from 48 h to
0.5 h prior to irradiation.
Having established an optimal radioprotective sLP dosing
regimen of 40 mg/kg injected sc 24 h before TBI, we tested this
regimen (versus PBS vehicle injection as a negative control) against
Figure 1. Synthetic lipopeptide (sLP) protects mice from radiation-induced death. (A) Dose-dependence of sLP-mediated radioprotection.
Female ICR (CD-1H) mice were injected sc with sLP (4, 12, 40, 120, 400, or 1200 mg/kg; n=15/group; average mouse weight 2562 g) or PBS vehicle
(n=10). Mice were irradiated with 10 Gy TBI 24 h after injection and monitored for survival for 30 days. The average 30-day survival from 3
independent experiments is presented. Error bars indicate standard error. No animals in the PBS-injected control group survived to day 30. The
differences in 30-day survival between sLP-treated and PBS-treated groups were statistically significant for sLP doses $12 mg/kg (as indicated by *,
P,0.05, Fisher’s Exact Test). (B) Time window for effective pre-irradiation administration of sLP. Female ICR mice (n=15/group) were injected sc with
sLP (40 mg/kg) at the indicated time points before irradiation with 10 Gy TBI (30 min, 1, 3, 6, 12, 24, 36, 48, or 72 h before TBI at time ‘‘0’’). The control
group (n=15) was injected with PBS 24 h before 10 Gy TBI. The average 30-day survival in each group in 2 independent experiments is shown. Error
bars indicate standard error. Injection of sLP at all times except for 272 h resulted in statistically significant improvement in 30-day survival relative to
PBS treatment (P,0.05, Fisher’s Exact test). (C) Determination of the dose reduction factor (DRF) for the optimal radioprotective regimen of sLP
administration. Probit analysis was performed using Kaplan-Meier survival curves generated from treatment of female ICR mice with PBS vehicle or
40 mg/kg sLP at 24 h prior to exposure to different TBI doses (see figure S1).
doi:10.1371/journal.pone.0033044.g001
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TBI required rangesof7–10Gyfor the vehicle-treated groups(Figure
S1A) or 10–13 Gy for the sLP-treated groups (Figure S1B). The
LD50/30 was found to be 8.5 Gy for vehicle-treated mice and 11.25
Gy for sLP-treated mice using probit analysis (see below). Thus, it is
clear that sLP allows mice to survive exposure to higher radiation
doses than vehicle. However, there was a limit to the level of TBI
against which sLP was able to protect a significant number of mice.
While sLP provided complete protection of mice from 10 Gy TBI
(100% 30-day survival), its efficacy was lower at higher TBI doses.
Thirty-day survival in sLP-treated groups exposed to 10.5, 11.0, 11.5,
12.0, and 13.0 Gy TBI was 87%, 63%, 28%, 13%, and 0%,
respectively (Fig. S1B).Given the well-defined preference of HP-ARS
orGI-ARS-inducedmortalitybydifferentlevelsofradiationexposure
[4], the dramatic difference in the ability of sLP to improve survival of
ICR mice irradiated with 10 Gy versus 12 Gy suggests that this agent
is effective only against HP-arm of ARS.
The survival curves established for vehicle and sLP treatment at
different TBI doses (Figure S1A,B) were used to determine the
dose reduction factor (DRF) for sLP using probit analysis
(Figure 1C). DRF, defined as the ratio of LD50/30 between drug-
and vehicle-treated groups, is a standard means for quantifying the
radioprotective efficacy of drugs. This analysis revealed that sLP
increased the LD50/30 in the ICR mouse model from 8.5 Gy to
11.25 Gy, yielding a DRF of approximately 1.32. The slopes of the
probit lines for the drug- and vehicle-treated groups were not
substantially different; however, the probit line for the drug-treated
groups was shifted significantly to the right (p,0.05).
sLP acts as a radiomitigator to improve mouse survival
when administered after irradiation
Having demonstrated significant radioprotective efficacy for sLP
administered prior to radiation exposure, we evaluated whether sLP
could also act as a radiomitigator and improve mouse survival when
injected afterirradiation.Female ICRmice wereinjected sc with sLP
or PBS at different times after TBI and monitored for survival. sLP
did not improve 30-day survival when administered to mice at any
time point after exposure to TBI doses of 10 Gy (LD100/30)o r
greater. However, at lower TBI doses (e.g., LD50/30–LD90/30, 8.5–9
Gy), sLP treatment led to significantly improved 30-day survival as
compared to vehicle treatment (data not shown). For mice exposed
to 9 Gy TBI, injection of sLP at all tested times of administration
from 10 min to 24 h post-irradiation increased 30-day survival
relative to PBS injection (Figure 2A). Injection of sLP 48 h after 9
Gy TBI did not have any beneficial effect on mouse survival. The
observed sLP-mediated survival benefit was statistically significant
for administration at 10 and 30 min and 1, 3, and 24 h post-
irradiation (p,0.05),but not for administration at 6, 9, or 12 h post-
irradiation. Thus, sLP showed significant radiomitigative efficacy
when injected as a single dose as late as 24 h after radiation
exposure. However, since the greatest degree of radiomitigation was
observed with injection of sLP 1 h after TBI (73% survival versus
7% in the vehicle-treated group, p=0.0002), this time point was
selected as the optimal time point for radiomitigation by sLP.
The DRF for post-irradiation administration of sLP was
determined using probit analysis as described above for the pre-
irradiation regimen of sLP treatment. Thirty-day survival curves
were established for groups of female ICR mice injected with
50 mg/mouse sLP 1 h after exposure to 7.5, 8.0, 8.5, 9.0, 9.5, or
10 Gy TBI (Figure S2A). The LD50/30 for this regimen of sLP
treatment was found to be approximately 9.25 Gy as compared to
8.5 Gy for vehicle treatment, indicating a DRF of 1.09 (Figure 2B).
This is illustrated by the slight shift in the probit line for sLP
treatment to the right as compared to the line for vehicle
treatment; however, the difference between the drug- and vehicle-
treated groups was not significant (p.0.05). The different slopes of
the probit lines for drug- and vehicle-treated groups is illustrative
of the lack of sLP-mediated radiomitigation at higher TBI doses
(e.g., 9.5–10 Gy) as compared to lower doses (e.g., 8.5–9.0 Gy).
Despite its relatively low DRF for radiomitigation, it is clear that
following certain TBI doses, sLP injection effectively mitigates
radiation-induced death (Figure 2, S2A). In fact, we found that a
single dose of 50 mg/mouse sLP given 3 h after 8 Gy TBI was as
effective in rescuing C57BL/6 mice as 16 daily post-irradiation
injections of recombinant G-CSF (NeupogenH, Amgen, Inc.), the
current standard of care for myelosuppression associated with
cancer treatment (Figure S2B). Survival was increased from 70%
(21/30) in the PBS-treated group to 96.7% (29/30) and 96.2%
(25/26) in the sLP at +3 h and G-CSF616 treatment groups,
respectively. When given as late as 24 h post-TBI, the single dose
of 50 mg/mouse sLP increased survival to 90% (27/30). The
increases in survival afforded by sLP at +3 h and G-CSF were
statistically significant relative to the PBS control (p=0.006 and
p=0.014, respectively), while survival increase by injection of sLP
at +24 h was marginally significant compared to PBS (p=0.054).
There were no statistically significant differences in survival
between any of the treated groups in this experiment.
sLP is efficacious in the context of low dose rate total
body irradiation
The experiments described above, as well as the majority of
those reported in the radiobiology field, were performed with
equipment that delivers radiation at a high dose rate (0.1–1 Gy/
min), such that LD30–100/30 doses are achieved within a matter of
minutes. While the radiomitigative efficacy of sLP under such
conditions is important, we also wished to evaluate the radio-
mitigative potential of sLP under another realistic scenario of
irradiation that involves high dose radiation received at a low dose
rate. We first established that, in female ICR mice, delivery of
approximate LD50 and LD90 doses of TBI at a rate of 0.4 cGy/
min required 60 and 70 h of continuous irradiation, respectively
(data not shown). Assessment of the morphology of the small
intestine in morbid animals following irradiation under these
conditions indicated that gastrointestinal (GI) damage was
insignificant; therefore, damage to the HP system is likely to play
a primary role in the lethality of these low dose rate irradiation
regimens (data not shown). We next performed a survival
experiment in which groups of mice were irradiated at 0.4 cGy/
min for 60 or 70 h and injected sc with either PBS or 10 mg/
mouse sLP half-way through the irradiation period (i.e., at 30 or
35 h after the start of irradiation). As shown in figure 2C, under
both scenarios of ‘‘low dose rate’’ TBI, injection of sLP
significantly improved 30-day survival of mice. With 60 h of
irradiation (14.4 Gy TBI), 30-day survival was 100% (15/15) in
the sLP-treated group as compared to 40% (6/15) in the PBS-
treated group. Administration of sLP at the mid-point of 70 h of
irradiation (16.8 Gy TBI) increased survival from 20% (3/15) in
the PBS-treated group to 80% (12/15) in the sLP-treated group.
For both TBI doses, the survival benefit provided by sLP
treatment was statistically significant (p,0.05).
sLP treatment promotes recovery of the hematopoietic
system following irradiation
As described above, the TBI dose range against which sLP
demonstrated radioprotective efficacy suggested that the drug is
specifically effective in protecting and/or promoting regeneration of
cells and tissues of the HP system (as opposed to cells of the GI tract).
Toll-Like Receptor 2 (TLR2) Activation and ARS
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treatment survived for at least 9 months with no evidence of
hematopoietic failure and showing normal structure and cellularity of
hematopoietic and lymphoid organs (data not shown). This indicates
that sLP induced long-term repopulation/recovery of the HP system.
The beneficial effect of sLP on the HP system in irradiated animals
was directly demonstrated by our finding that sLP pretreatment
accelerated recovery of cellularity of both the bone marrow and
spleen in BALB/c mice exposed to a sub-lethal dose of 4 Gy TBI
(Figure S3). Moreover, we showed that sLP reduced the severity of
radiation-induced thrombocytopenia and accelerated recovery of
circulating platelet levels (data not shown). This is a highly relevant
finding since the severity of radiation-induced thrombocytopenia has
been identified as the HP marker that is most closely correlated with
radiation-induced mortality in primates [38].
Administration of sLP leads to induction of multiple
cytokines with potential roles in radioprotection and
recovery of the hematopoietic system
In order to gain insight into the mechanism(s) underlying the
radioprotective/mitigative activity of sLP, we assessed whether
sLP treatment of mice affected their serum levels of various
Figure 2. Radiomitigation by sLP: administration of sLP after lethal TBI improves mouse survival. (A) Time window for effective post-
irradiation administration of sLP. Female ICR (CD-1H) mice (n=15/group) were irradiated with 9 Gy TBI (at time ‘‘0’’) and then injected sc with PBS at
1 h after irradiation or with sLP (50 mg/mouse) at 10 or 30 min, or 1, 3, 6, 9, 12, 24, or 48 h after irradiation. Mouse survival was monitored for 30 days.
The differences in 30-day survival between the vehicle-treated group and groups treated with sLP between 10 min and 3 h after TBI and at 24 h after
TBI were statistically significant (as indicated by *, P,0.05, Fisher’s Exact test). (B) Determination of the DRF for the optimal radiomitigative regimen of
sLP administration. Probit analysis was performed using Kaplan-Meier survival curves generated from treatment of female ICR mice with PBS vehicle
or 50 mg/mouse sLP at 1 h after exposure to different TBI doses (see figure S2A). (C) SLP-mediated mitigation of death induced by low dose rate
irradiation. Female ICR (CD-1H) mice (n=15/group) received TBI at a continuous exposure rate of 0.4 cGy/min for 60 or 70 h (total dose of 14.4 or 16.8
Gy, respectively). At the mid-point of the irradiation period (i.e., 30 or 35 h after irradiation was started for the 60 and 70 h TBI groups, respectively),
irradiation was halted for about 5 min during which time mice were injected sc with 10 mg/mouse sLP. Mouse survival was monitored for 30 days.
doi:10.1371/journal.pone.0033044.g002
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(i) sLP counteracted HP syndrome and cytokines are known to
regulate survival and proliferation of HP cells, (ii) many cytokine-
encoding genes are transcriptional targets of NF-kB, which is
activated downstream of sLP-TLR interaction, and (iii) a number
of cytokines were previously shown to have radioprotective
efficacy [8]. Therefore, we collected blood samples from groups
of 6 female C57BL/6 mice per time point at 1, 2, 4, 8, 24, and
48 h after sc injection of 10 mg/mouse sLP (without irradiation).
Blood samples from 6 untreated female C57BL/6 mice were
collected for use as a baseline control (referred to as time ‘‘0’’).
Analysis of blood serum samples in multiplex Luminex assays
provided quantitation of G-CSF, IL-6, KC, IL-1b, IL-10, IL-
12(p70), SCF, granulocyte macrophage colony-stimulating factor
(GM-CSF), and tumor necrosis factor (TNF) levels (Figure 3A,B).
All of the tested cytokines showed transient induction following
sLP administration, but the extent of induction was much higher
for IL-6, G-CSF and KC than for the other induced cytokines.
Peak levels of IL-6, G-CSF, and KC were 34,000-, 10,000- and
5,000-fold higher than baseline, respectively. In contrast, peak
levels of other induced cytokines were in the range of 50- to 375-
fold higher than baseline. Levels of IL-6, G-CSF and KC were
increased at the earliest tested time point (1 h post-injection) and,
for IL-6 and KC, peaked 2 h after injection and returned to
baseline within 8–24 h post-injection. Induction of G-CSF by sLP
was unique among the tested cytokines both in the strength of the
response (fold increase over baseline) and its duration. G-CSF
levels peaked at 8 h post-injection, but high levels (more than
20,000-fold over baseline) persisted from 2 h to 24 h post-
injection, only returning to baseline at 48 h after injection. As
shown in Figure 3B, IL-1b, IL-10, IL-12(p70), SCF and TNF also
showed induction within the first several hours after sLP
administration, peaking at 2–4 h post-injection and declining to
baseline within 24–72 h. GM-CSF was distinct in that it showed
very moderate induction as compared to the other tested
cytokines. These results demonstrate that sLP treatment induces
multiple cytokines and suggests that activity of the induced
cytokines may underlie, at least in part, the radioprotective/
mitigative effects of sLP. The list of cytokines that were measured
but did not change in response to sLP administration includes
TPO, IL1a, IFN-c, IL-2, IL-3, IL-4, and IL-11(data not shown).
The radioprotective/mitigative activity of sLP requires
TLR2 signaling
It is well documented that BLPs and their synthetic analogs
interact with heterodimeric cell surface receptors comprised of
TLR2 paired with either TLR6 or TLR1 and that this results in
activation of NF-kB signaling [39,40,41]. We have shown that sLP
treatment produces dose-dependent activation of NF-kB-depen-
dent reporter gene expression in cultured cells expressing TLR2/6
or TLR2/CD14 receptor heterodimers, but not in TLR-negative
cells (data not shown). To confirm that the in vivo radioprotective
activity of sLP is dependent upon its interaction with TLR2
receptor complexes, we compared its effects in TLR2 knockout
(KO) mice and isogenic wild type (WT) control C57BL/6J mice
(see Materials and Methods). WT and TLR2 KO C57BL/6J mice
were exposed to 9 Gy TBI 24 h after sc injection of PBS or sLP
(3 mg/mouse). At 30-days post-irradiation, there were no surviving
PBS-treated WT mice (0/15), confirming 9 Gy TBI as the LD100/
30 for C57BL/6J mice (Figure 4A). In contrast, 100% (15/15) of
WT mice that received sLP prior to 9 Gy TBI survived to day 30
post-irradiation. In TLR2 KO mice, sLP pre-treatment did not
ameliorate radiation-induced death. Thirty-day survival was 0%
(0/15) in the sLP-treated TLR2 KO group and 13% (2/15) in the
corresponding PBS-treated group. These data clearly indicate that
TLR2-containing receptor complexes are required for sLP-
mediated radioprotection.
Responses of both bone marrow and non-bone marrow
cells contribute to sLP-mediated radioprotection and
cytokine induction
Having determined that TLR2 expression is critical for sLP-
mediated radioprotection/mitigation, we generated TLR2 KO/
wild type chimeric mice to evaluate the roles of bone marrow
(BM)-derived cells versus other cell types in this effect. Reciprocal
BM mouse chimeras were generated as follows: TLR2 KO or wild
type (WT) C57BL/6 ‘‘recipient’’ mice were lethally irradiated
(266 Gy TBI 24 h apart) and then transplanted with BM cells
(5610
6 cells/recipient mouse) from TLR2 KO or WT C57BL/6
‘‘donor’’ mice (untreated and unirradiated). The level of
chimerism in the transplanted mice was checked 60 days later
by FACS analysis as described in Materials and Methods. Only
chimeric mice with .95% of peripheral blood cells displaying
surface antigens specific to the BM donor mouse strain were used
in subsequent experiments.
Groups of 8 chimeric mice for each of the four types ((i)
TLR2KO BM transplanted into TLR2KO background
(‘‘TLR2KO-to-TLR2KO’’), (ii) TLR2KO BM into WT back-
ground (‘‘TLR2KO-to-WT’’), (iii) WT BM into TLR2KO
background (‘‘WT-to-TLR2KO’’) and (iv) WT BM into WT
background (‘‘WT-to-WT)) were tested for sLP-mediated radio-
protection. Mice were injected sc with 20 mg of sLP and then
irradiated 24 h later with 9 Gy TBI. As expected based on our
results with non-chimeric WT mice, ‘‘WT-to-WT’’ chimeras were
protected from radiation-induced death by sLP pretreatment (88%
30-day survival, figure 4B). Similarly, WT mice transplanted with
TLR2-negative BM cells (‘‘TLR2KO-to-WT’’ chimeras) were
fully protected (100%). On the other hand, mice completely
deficient in TLR2 (‘‘TLR2KO-to-TLR2KO’’ chimeras) were not
protected (0% 30-day survival) and mice with TLR2 expression
only in the BM (‘‘WT-to-TLR2’’ chimeras) were only partially
protected (50% survival). Our unrelated studies using another
mouse strain (CD2F1) with BMT after lethal irradiation
demonstrated that mice did not show altered sensitivity to TBI
after they recovered from transplantation of syngeneic bone
marrow (data not shown). These data show that TLR2 expression
in BM cells is partly dispensable for sLP-mediated radioprotection,
while TLR2 expression in non-BM cells is not.
We next treated the four established types of chimeric mice
(‘‘WT-to-WT’’, ‘‘TLR2KO-to-WT,’’ ‘‘WT-to-TLR2KO’’ and
‘‘TLR2KO-to-TLR2KO’’) with sLP in the absence of radiation
to determine the contributions of BM- and non-BM cells to sLP-
mediated cytokine induction. Twenty animals of each type of
chimeric mice (10M+10F) were injected with 20 mg/kg of sLP. At
time points 0 (before injection), 1 h, 2 h, 4 h, and 8 h after
injections 4 mice/time point (2M and 2F) were euthanized, blood
was collected and used to prepare serum for measurement of
cytokine levels using multiplex Luminex assays. The Total
Amount of Produced Cytokines (TAPC) was calculated as the
sum of the amount of cytokine at all measured time points after
sLP injection and averaged for the four animals in each group.
These mean TAPC values are presented as a percentage of the
mean value for the ‘‘WT-to-WT’’ chimeric group in Figure 4C.
The level of G-CSF in the serum of sLP-treated ‘‘TLR2KO-to-
WT’’ chimeric mice was similar to (89% of) that in ‘‘WT-to-WT’’
mice. However, sLP-mediated induction of G-CSF was much
lower in ‘‘WT-to-TLR2KO’’ mice (4% of the ‘‘WT-to-WT’’
value) and essentially absent in ‘‘TLR2KO-to-TLR2KO’’ mice.
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requires TLR2. However, since chimeric mice with TLR2-
negative BM cells on a WT background showed the same G-
CSF response to sLP as completely WT mice, it is clear that direct
response of BM cells to sLP is not involved in the observed
upregulation of G-CSF. Rather TLR2 expression in the mouse
background (non-BM cells) is critical for G-CSF induction. All of
the other tested cytokines (IL-1b, IL-6, IL-10, IL-12(p70), GM-
CSF, KC, and TNF-a) showed a similar pattern of expression in
the different chimeras: the level of induction was closest to ‘‘WT-
to-WT’’ in ‘‘TLR2KO-to-WT’’ chimeric mice, reduced in ‘‘WT-
to-TLR2KO’’ mice, and lowest in ‘‘TLR2KO-to-TLR2KO’’
animals. Like G-CSF, IL-6 and KC showed essentially no sLP-
mediated induction in mice completely deficient in TLR2
(‘‘TLR2KO-to-TLR2KO’’ chimeras), while the other tested
cytokines showed residual induction (,10–30% of ‘‘WT-to-WT).
The contribution of BM was greater for sLP-induced cytokines
other than G-CSF; however, in all cases it was clear that non-BM
cells also play a role (TLR2 expression in the mouse background
led to higher levels of cytokine induction).
Taken together, the results obtained with TLR2KO-WT
chimeric mice demonstrate that the beneficial effect of sLP on
the HP system following irradiation is at least partially indirect
(i.e., not mediated by a direct response in radiosensitive BM cells).
Additionally, the data suggest that (i) G-CSF is likely the main
mediator of the radioprotective efficacy of sLP (since sLP
specifically protects ‘‘TLR2KO-to-WT’’ chimeras and G-CSF
shows a unique profile of induction in mice of this genotype), (ii)
cytokines other than G-CSF might act to potentiate the effect of
sLP on post-irradiation survival (since sLP partially protected
‘‘WT-to-TLR2KO’’ chimeric mice and there is very little G-CSF
induction in this genotype, although other cytokines are induced),
and (iii) the low levels of induction of other cytokines observed in
sLP-treated ‘‘TLR2KO-to-TLR2KO’’ chimeras are not involved
in protection of mice from radiation-induced death or at least are
not sufficient to confer such protection.
Figure 3. Administration of sLP in mice results in cytokine induction. Non-irradiated female C57BL/6 mice were injected sc with 10 mg sLP
and euthanized 1, 2, 4, 8, 24, or 48 h later (n=6/time point) for blood collection. Blood from untreated female C57BL/6 mice (n=6) was analyzed as
the ‘‘0 hour’’ time point. G-CSF, IL-6, and KC (A) and IL-1b, IL-10, IL-12(p70), SCF, GM-CSF, and TNF-a (B) levels were determined in individual mouse
serum samples using multiplex Luminex assays. The mean cytokine concentration at each time point is shown. Error bars indicate standard error.
doi:10.1371/journal.pone.0033044.g003
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This work demonstrates the radioprotective and radiomitigative
capacity of sLP that mimic the N-terminal structure of naturally
occurring mycoplasmal lipoproteins and their ability to activate
NF-kB via TLR2-containing receptors. sLP is notable in that it
significantly increases survival of lethally irradiated mice when
administered as a single injection as early as 48 h before
irradiation or as late as 24 h after irradiation. While sLP is
effective as a radiomitigator injected after TBI, its efficacy is
greater when administered before TBI. When injected at the
optimal prophylactic time of 24 h before TBI, sLP increased 30-
day survival of ICR mice exposed to 10 Gy TBI from 0% to 100%
(Fig. 1). The DRF for sLP administered to ICR mice prior to
irradiation was calculated to be 1.32. This indicates that the TBI
dose needed to cause 50% lethality within 30 days was 1.32-fold
higher in sLP-treated mice than in vehicle-treated mice. This DRF
is in the same range as those for many other proposed radiation
countermeasures (e.g., Vitamin E (a-tocopherol) with a DRF of
1.23 [42], 5-AED with a DRF of 1.26 [43], SCF with a DRF in the
range of 1.3–1.35 [14], etc.). Nevertheless, there are examples of
compounds with higher DRFs (e.g., amifostine with a DRF up to
Figure 4. sLP-mediated radioprotection and cytokine induction is TLR2-dependent and involves both bone marrow and non-bone
marrow cells. (A) TLR2-dependence of sLP-mediated radioprotection. Groups of isogenic TLR2(2/2) and wild type C57BL/6 mice (n=15/group)
were injected sc with vehicle (PBS) or sLP (3 mg/mouse) and irradiated (9 Gy TBI) 24 h later. Survival was monitored for 30 days. (B) sLP-mediated
radioprotection in chimeric mice with wild type (WT) or TLR2(2/2) (TLR2KO) bone marrow (BM). Reciprocal radiation BM chimeras were generated as
described in Results and Materials and Methods. Four types of chimeric mice, (i) TLR2KO BM transplanted into TLR2KO background, (ii) TLR2KO BM
into WT background, (iii) WT BM into TLR2KO background, and (iv) WT BM into WT background, were injected sc with 20 mg/mouse sLP and irradiated
with 9 Gy TBI 24 h later (n=8/group). Survival was monitored for 30 days. (C) sLP-mediated cytokine induction in chimeric mice with WT or TLR2KO
BM. The four types of chimeric mice described in (B) were injected with 20 mg/kg sLP without irradiation. Four sLP-injected mice of each genotype (2
males and 2 females) were euthanized at each time point (1, 2, 4, and 8 h post-injection) and serum cytokine levels of individual mice were
determined using multiplex Luminex assays. The AUC for each cytokine was calculated as described in Materials and Methods and is presented for
‘‘TLR2KO to TLR2KO’’, ‘‘TLR2KO-to-WT’’, and ‘‘WT-to TLR2KO’’ chimeric mice as the percentage of that in ‘‘WT-to-WT’’ chimeric mice.
doi:10.1371/journal.pone.0033044.g004
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of 1.6 [33]). It should be noted, however, that sLP has an
important advantage over some other compounds in the context of
prophylactic use since it is practically non-immunogenic. This
overcomes the biggest problem associated with repeated admin-
istration of CBLB502.
Another important advantage of sLP is that, in addition to
acting as a radioprotectant, it is also effective as a radiomitigator
administered after radiation exposure has occurred. Athough post-
irradiation treatment with sLP was not effective against 10 Gy TBI
and the maximal increase in survival observed in ICR mice after 9
Gy TBI was 65% (Fig. 2), the observed radiomitigative efficacy of
sLP is nevertheless a relatively unique feature among MRC under
development and is clearly important for potential use in
biodefense applications in which advance warning of radiation
exposure is not likely to be available. Radiomitigative efficacy has
also been demonstrated for vitamin E [44] and the TLR5 agonist
CBLB502 [33], whereas amifostine is not effective when
administered after exposure [45]. We speculate that the lower
DMF (efficacy) observed with post-irradiation (mitigative) sLP
treatment as compared to pre-irradiation treatment might be
explained as follows: when applied after irradiation, the ability of a
drug to suppress apoptosis in damaged cells can no longer
contribute to its efficacy, only its ability to stimulate regeneration
can. This hypothesis can be tested in future detailed studies of the
efficacy and mechanism of action of sLPs as radiation counter-
measures.
An additional feature of sLP treatment that can be noted as a
benefit in terms of likely biodefense applications is that this agent is
effective against high dose TBI delivered at a high or low dose rate
(as tested in this study, within several minutes or over 60–70 hours,
respectively). It is not clear whether other radiation countermea-
sures share this feature since low dose rates have not been tested in
most previous studies. sLP also has the advantage of being
efficacious as a single injected dose. While this characteristic is
particularly important for biodefense applications, it provides a
clear benefit even in medical scenarios over drugs such as G-CSF
(NeupogenH) which requires multiple daily injections for up to 2
weeks in chemotherapy patients.
The radioprotective and radiomitigative effects of sLP are
limited to doses of TBI that cause primarily HP syndrome-
dependent mortality. While sLP’s lack of efficacy against higher,
GI syndrome-inducing TBI doses may be viewed as a disadvan-
tage vis-a `-vis countermeasures such as amifostine and CBLB502,
HP-specific radiation countermeasures can be projected to have a
significant impact in many biodefense and medical scenarios in
which both short-term mortality and long-term health conse-
quences stem from radiation damage to the HP system. In this
communication, we report that sLP treatment accelerated
regeneration of radiation-depleted bone marrow cells, spleen cells,
and thrombocytes. Ongoing experiments are focused on more
precisely defining the effects of sLP on different tissues and cell
lineages of the HP system, such as hematopoietic stem cells.
In terms of mechanism of action, testing of sLP in TLR2
knockout (KO) mice confirmed that the ability of sLP to reduce
the lethality of TBI is dependent upon TLR2. Moreover, through
analysis of TLR2 KO/WT bone marrow chimeras, we showed
that TLR2 responses to sLP in both BM and non-BM cells
contribute to the radioprotective efficacy of this agent. This
indicates that the beneficial effects of sLP on HP cells are
mediated, at least in part, through indirect, non-cell autonomous
mechanisms. The involvement of such indirect mechanisms is
consistent with the capacity of sLP to reduce radiation damage
even when administered after radiation exposure. Therefore, the
anti-ARS activity of sLP likely involves multiple mechanisms
including direct protection of radiosensitive cells (via activation of
NF-kB-dependent anti-apoptotic factors) as well as indirect effects
mediated by sLP-induced cytokines (see below) or other factors
produced by BM-derived cells as well as cells outside the HP
system. Such indirect effects might impact both preservation of HP
tissue cellularity (protection against cell death) and stimulation of
tissue regeneration.
Injection of sLP resulted in strong transient induction of a
number of cytokines with known roles in hematopoiesis, including
G-CSF, KC, and IL-6. Thus, sLP-induced cytokines are likely to
mediate, at least in part, the radioprotective/mitigative activity of
this countermeasure. In particular, G-CSF is a promising
candidate mediator of sLP’s radioprotective activity due to its
striking induction following sLP injection (Fig. 3A) and its known
biological effects. Recombinant G-CSF (NeupogenH) is currently
widely used in the clinic to facilitate recovery of the HP system in
situations such as bone marrow transplantation and chemother-
apy. However, we found that a single injection of sLP was just as
effective as 16 daily injections of NeupogenH in increasing survival
of irradiated mice (Fig. S2B). The efficacy of sLP likely derives
from its ability to not only induce G-CSF, but also multiple other
cytokines that impact HP cell differentiation, proliferation, and
survival. Therefore, sLP can be projected to be preferred as a
radiation countermeasure over single cytokine therapies. It would
be interesting to evaluate changes in cytokine levels when sLP is
applied after irradiation to define the mechanisms responsible for
the observed dependence of efficacy on the time of drug injection
relative to irradiation. Notably, the TLR5 agonist CBLB502
produces a cytokine response that is very similar to that induced by
sLP [33], but protection/mitigation of GI ARS is only seen with
CBLB502, and not with sLP. This suggests that the induced
cytokines are not involved in, or at least not sufficient for, altering
the course of radiation-induced events in GI cells.
Overall, this study illustrates the strong potential of sLP-based
TLR2 agonists for radioprotection and mitigation in defense and
medical scenarios. The biodefense indication is key given the risk
level in today’s world and the fact that there are currently no FDA-
approved radiation countermeasures suitable for use in mass-
exposure scenarios [46]. Medical use of sLP for protection against
cancer treatment side effects would also have a substantial impact
on human health. However, development of sLP in this direction
will require clarification of some critical issues. Foremost, does sLP
protect not only normal cells, but also tumors, against radiation-
induced killing? Although this remains to be tested directly for sLP,
our previous work with the TLR5 agonist CBLB502 indicated that
the anti-radiation effects following from activation of NF-kB via
TLR stimulation were indeed specific to normal cells [33] and,
therefore, not sensitive to the stimulatory effects of TLR agonists.
Intratumoral administration in humans [47] or systemic admin-
istration in experimental tumor models in mice [48] demonstrated
that sLP administration is not only safe during anti-cancer
therapy, but provides survival benefits as well. Moreover, TLR-
mediated NF-kB signaling is known to activate both the innate
and adaptive immune systems, including anti-tumor immunity
[49,50,51,52]. Thus, temporary activation of NF-kB by sLP might
not only result in radioprotection of normal tissues, but also reduce
the incidence of secondary cancers due to the simultaneous
immunostimulatory effect of NF-kB activation. Second, does sLP
treatment have any positive effect on tumor growth or metastasis?
This will be important to resolve given a recent report [53]
indicating that TLR2 agonism can stimulate metastasis. Third, is
sLP effective against radiation delivery characteristic of anti-cancer
radiotherapy regimens (e.g., local fractioned irradiation)? This has
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and is readily testable for sLP. Ongoing work is focused on
resolving these issues and developing optimized sLP for use as safe,
practical and effective radiation countermeasures. The data herein
provide a strong foundation for these efforts, demonstrating that
sLP has a number of promising characteristics including a broad
time window for effective administration, attractive DRF, efficacy
against slowly delivered radiation, and capacity to induce
cytokines with desirable activities.
Materials and Methods
Mice
Female 10–12 week-old ICR(CD1) mice were purchased from
Harlan (Indianapolis, IN). Female 10–12 week-old BALB/cJ,
C57BL/6J, B6.SJL-Ptprc
a Pepc
b/BoyJ, and breeding pairs of
TLR2(2/2) mice (C57BL/6 genetic background after 11 back-
crosses) were purchased from the Jackson Laboratory (Bar Harbor,
ME). All mice were housed (up to 5 mice per cage with exception of
ICR - 4 mice per cage) in an air-conditioned facility accredited by
the Association for Assessment and Accreditation of Laboratory
Animal Care International. Allmiceweremaintained in rooms on a
12-h light/dark cycle, at 2162uC, with 10–15 hourly cycles of fresh
air, and relative humidity of 50610%. Upon arrival, the mice were
held in quarantine for 1 week and provided certified rodent rations
and acidified water (HCl, pH=2.5–2.8) ad libitum. All animal
procedures were performed according to protocols approved by
Institutional Animal Care and Use Committees of the Cleveland
Clinic Foundation (CCF), Roswell Park Cancer Institute (RPCI),
and Indiana University. Research was conducted according to the
Guide for the Care and Use of Laboratory Animals prepared by the
Institute of Laboratory Animal Resources, National Research
Council, U.S. National Academy of Sciences.
Irradiation
For all experiments except those shown in Figures 2C and S2B
(described below), mice were exposed to bilateral total body
irradiation (TBI) using J.L. Shepherd MK I-68
137Cs c-irradiators
located at Cleveland Clinic Foundation (dose rate=2.3 Gy/min
on the day of irradiation) or Roswell Park Cancer Institute (dose
rate=1.55 Gy/min on the day of irradiation). Dose rates were
recalculated daily. Mice were irradiated in a well-ventilated
Plexiglas bucket accommodating 8–10 mice per irradiation round.
The irradiation bucket was elevated on the irradiator turntable
using a 2 cm-high plastic riser in order to provide a more uniform
radiation field. For irradiation, mice from different treatment
groups were mixed and then returned to their corresponding
cages.
Experiments shown in Figure 2C (low dose rate irradiation)
were conducted at Colorado State University (Fort Collins, CO)
using a J.L. Shepherd Model 81 S/N 7014
137Cs (600Ci) c-
irradiator with a dose rate 0.4160.05 cGy/min under CSU
IACUC protocol #07 - 239A. Sustained irradiation for 60 or
70 hours provided total irradiation doses of 14.4 Gy and 16.8 Gy,
respectively.
The experiment shown in Figure S2B was performed at the
Indiana University School of Medicine (Indianapolis, IN). Groups
of C57BL/6 mice were irradiated using a GammaCell 40
137Cs c-
irradiator (Nordion International, Kanata, Ontario, Canada) with
a dose rate of 675 cGy/min to achieve a total dose 7.96 Gy.
Reagents
R-Pam2-CSKKKK (S-[(2R)-2,3-bis(palmitoyloxy)propyl]-cystei-
nyl-SKKK) and other sLP were purchased from EMC micro-
collections GmbH (Tuebingen, Germany) as pure dry powder.
The powder was reconstituted in D-PBS at a concentration of
2.5 mg/ml and stored as a stock solution for up to 6 months at
+4uC. Final desired dilutions were made in D-PBS just before
administration. Each vial of NeupogenH (Amgen, Inc., Thousand
Oaks, CA) contained 300 mg of r-metHuGCSF (at a specific
activity of 1.060.66108 Units/mg; 30 million total units/vial) in a
total volume of 1 ml. NeupogenH was stored at 4uC and
administered to mice at a dose of 2.5 mg/mouse/day (,125 mg/
kg/day dose based on expected average mouse weight of 20 g;
actual average mouse weights were 15–21.5 g and 19–28 g for
females and males, respectively, on the day before TBI). All
substances were administered to mice via subcutaneous or
intraperitoneal injections without anesthesia.
Preparation of WT and TLR5KO bone marrow cells for
generation of bone marrow chimeras
Preparation of bone marrow single cell suspensions was
performed as previously described [55]. Briefly, 4 bones per
mouse (2 tibias and femurs) from 3 donor mice of each genotype
were flushed with 1 ml medium (Iscove’s +0.5% BSA, no
antibiotics) into 5 ml round-bottomed tubes. Cell suspensions
were filtered through a 40 mm strainer into a 50 ml tube. Washed
cells were collected by centrifugation and resuspended in 2.0 ml
medium for counting of nucleated cells. After counting, the
volume was adjusted to have ,5610
6 cells/recipient in 0.2 ml
volume.
Preparation of spleen cells
Single cell suspensions from spleens were prepared as described
[56]. Viable (trypan blue-excluding) cells were counted under a
microscope.
Preparation of mouse bone marrow (BM) radiation
chimeras
Four types of reciprocal radiation BM chimeras were preapred:
TLR2 (2/2) mice reconstituted with either TLR2 (2/2) or wild
type (WT) BM cells and WT mice reconstituted with either TLR2
(2/2) or WT BM cells. B6.SJL-Ptprc
a Pepc
b/BoyJ (CD45.1) mice
were used as the WT counterpart to TLR2 (2/2) mice on a
C57BL/6 (CD45.2) genetic background. Recipient mice were
exposed to two rounds of TBI (6 Gy/round) 24 h apart. Within
3 hours after the second dose of TBI, recipient mice were injected
iv with 5610
6 BM cells prepared from unirradiated donor mice of
the appropriate genotype. Sixty days after BM transplantation,
100 /l of blood was obtained from the tail vein of recipient mice
and analyzed by FACS to determine the extent of chimerism in
each mouse. For FACS analysis, samples of whole blood were
stained with the following antibodies (2 /l/10
6 cells): CD45.1
FITC-labeled (11-0453-82), Ly-6G PE-labeled (12-5931-85),
CD19 PE-Cy5.5-labeled (35-0193-82), and CD45.2 APC-labeled
(17-0454-82) (eBioscience, San Diego, CA 92121). After 30 min
staining, red blood cells were lysed by adding 1 ml pre-warmed
(37uC) lysis buffer (00-4333-57, eBioscience) and mixing at room
temperature for 5 min. White blood cells were collected by
centrifugation at 400 g for 10 min at 4uC, resuspended in 300 ml
staining buffer (00-4222-57, eBioscience) and analyzed using a
four-color FACSCalibur instrument (Becton Dickinson, San
Diego, CA). BM chimeric mice were used in experiments only if
.98% of GR1
+ and CD11b
+ cells were donor-derived (positive for
CD45.1 or CD45.2 as appropriate depending upon donor
genotype) and if .90% of CD19
+ and CD3
+ cells were donor
derived.
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For cytokine analysis, blood was collected 1, 2, 4, 8, 24, or 48 h
after sLP injection. Blood was collected from mice by cardiac
puncture, transferred to CapiJect serum separator tubes (T-MQK,
TERUMO, Somerset, NJ), and centrifuged at 1000 rpm for
10 min.Serumwasstoredat270uCuntilusedforcytokineanalysis.
Serum levels of multiple cytokines were simultaneously
determined using cytokine analysis kits custom ordered
(M200003JZX) from Bio-Rad, Inc. (Hercules, CA) on with the
Luminex-200 dual-laser flow analyzer (Luminex Corp, Austin,
TX). Interleukin-1b (IL-1b), IL-6, IL-10, IL-12(p70), granulocyte
colony-stimulating factor (G-CSF), granulocyte macrophage
colony-stimulating factor (GM-CSF), keratinocyte-derived chemo-
kine (KC), and tumor necrosis factor-a (TNF-a) were measured.
The bead-based sandwich immunoassay kits from Bio-Rad
included all necessary reagents for cytokine analysis. Briefly,
anti-cytokine antibody-conjugated beads were added to wells of
flat-bottom 96-well plates (Bio-Rad, Inc.). Serum samples diluted
1:4 with the provided diluent were added to the wells. After
incubation, plates were washed using a Bio-Plex Pro wash station
(Bio-Rad, Inc.). Diluted detection antibody was added and plates
were incubated for 1 h. After washing again, streptavidin-
phycoerythrin was added. After final incubation and washing,
the signal from the bound fluorochrome was quantified using the
Luminex-200 analyzer. The instrument was calibrated with
calibration microspheres (Bio-Rad, Inc.). The median fluorescence
intensity of fluorochrome-conjugated antibody bound to individual
microspheres was derived from flow analysis of 50 microspheres/
region. For quantification of cytokines, standard curves were
plotted using standards supplied with kit. The intensity of the
fluorescence was directly proportional to the concentration of
cytokine. Calculations were performed using Bio-Plex Manger
software version 5.0 (Bio-Rad, Inc.). The Total Amount of
Produced Cytokines (TAPC) was calculated as the sum of the
amount of cytokine at all measured time points after sLP injection.
Statistical analysis
For survival experiments, the Log-Rank test was used to
compare the kinetics of mortality (mean survival time of
decedents). Fisher’s Exact test was used to compare survival rates
at the end of 30 days post-irradiation, with Bonferroni correction
used to control for type-I errors if multiple comparisons were used.
Results were considered statistically significant if p,0.05. All
statistical tests were two-sided. For calculation of does modification
factors (DRFs), Probit analysis was performed using the SPSS
statistical package (http://spss.en.softonic.com/).
Supporting Information
Figure S1 Effect of sLP pre-treatment on survival of
mice exposed to different doses of TBI. Thirty-day Kaplan-
Meier survival curves for groups of female ICR (CD-1H) mice
injected sc with vehicle (PBS, n=14) (A) or 40 mg/kg sLP (n=15)
(B) 24 hours before TBI with the indicated doses. TBI doses
ranging from 7 Gy to 10 Gy for vehicle-treated groups (A) and
from 10 to 13 Gy for sLP-treated groups (B) were used to cover
LD0–100/30 lethality ranges.
(TIF)
Figure S2 Effect of post-irradiation administration of
sLP on survival of mice exposed to different doses of
TBI. (A) Thirty-day Kaplan-Meier survival curves for groups of
female ICR (CD-1H) mice irradiated with the indicated TBI doses
(7.5 - 10 Gy) and injected sc with 50 mg/mouse sLP 1 hour after
TBI (n=15/group). (B) Comparison of sLP and NeupogenH
radiomitigation capacities. Groups of 30 C57BL/6 mice (15
males+15 females) were irradiated with 7.96 Gy TBI. Following
irradiation, groups were treated as follows: (i) single sc injection of
50 mg/mouse (,2.5 mg/kg dose based on expected average
mouse weight of 20 g) sLP 3 hours after TBI; (ii) single sc
injection of 50 mg/mouse sLP 24 hours after TBI; (iii) daily sc
injection of NeupogenH starting 24 hours after TBI and
continuing for 16 days at a dose of 2.5 mg/mouse/day
(,125 mg/kg/day dose based on expected average mouse weight
of 20 g); and (iv) single sc injection of vehicle (PBS) at 24 hours
after TBI. All groups contained 15 male and 15 female mice each,
except for the NeupogenH-treated group which contained 15
males and 11 females. Mouse survival was monitored for 30 days.
Fisher’s Exact tests were used to determine whether differences in
30-day survival were statistically significant.
(TIF)
Figure S3 Effect of sLP pre-treatment on radiation-
induced changes in mouse hematopoietic organs. Female
BALB/c mice (n=24/group) were injected ip with vehicle (PBS)
or sLP (3 mg/mouse) 24 h before exposure to 4 Gy TBI. Bone
marrow (from two femurs of each individual mouse) (A) and spleen
(B) cell suspensions were prepared (3 ml final volume) from 8 mice
euthanized on days 1, 7 and 14 after TBI. Bone marrow and
spleen cell suspensions were prepared similarly from 8 age-
matched naı ¨ve control mice were not injected or irradiated. Viable
(trypan blue-excluding) cells were counted under a microscope.
Error bars indicate standard errors.
(TIF)
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